Get Access to Quizartinib for Tablets in India               

Vanflyta (Quizartinib) is a kinase inhibitor used in conjunction with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, to treat adults with newly diagnosed AML (acute myeloid leukemia) that is FLT3-ITD-positive.

Recommended Dosage: The recommended dose of Vanflyta tablet is administered orally with or without food at around the same time each day. Swallow tablets whole. Do not crush, cut, or chew them. The recommended dose is as follows:

Induction: 35.4 mg taken orally once daily on Days 8 to 21 of “7 + 3” (cytarabine [100 or 200 mg/m2 per day] on Days 1 to 7 plus daunorubicin [60 mg/m2 per day] or idarubicin [12 mg/m2 per day] on Days 1 to 3) and on Days 8-21 or 6-19 of an optional second induction (“7 + 3” or “5 + 2” [5 days cytarabine plus 2 days idarubicin or daunorubicin], respectively),

Consolidation: 35.4 mg taken orally once daily on Days 6 to 19 of high‑dose cytarabine (1.5 to 3 g/m2 every 12 hours on Days 1, 3 & 5) for up to 4 cycles, and

Maintenance: 26.5 mg taken orally once daily on Days 1 to 14 and 53 mg once daily, thereafter, for up to thirty-six 28-day cycles.

If a dose is vomited, do not take a replacement dose; wait until the very next scheduled dose is due. If a dose is missed or not taken at the usual time, administer the dose as quickly as possible on the same day and return to the usual schedule the following day. The patient must not take a couple of doses on the same day.